MAAT.PA MaaT Pharma SA (EURONEXT) down 19% intraday: support near €5.14

We see MAAT.PA stock tumbling 19.38% on 31 Mar 2026 as MaaT Pharma SA (EURONEXT) trades at €5.24 intraday. The share opened at €5.78, hit a low of €5.14, and volume surged to 200,459 shares versus an average of 133,036. The move follows a weak earnings update and renewed analyst scrutiny in Europe’s biotechnology sector. We outline drivers, valuation, technicals and short-term price targets for traders watching MAAT.PA stock today.

MAAT.PA stock intraday price action

Intraday, MAAT.PA stock fell from the previous close of €6.50 to €5.24, a €1.26 drop or -19.38%. The high was €5.80 and low €5.14, indicating selling pressure through the session. Volume of 200,459 shows above-average interest, suggesting traders are reacting to fresh company or sector signals.

Key drivers and recent MAAT.PA news

MaaT Pharma SA is a clinical-stage biotechnology firm focused on microbiome biotherapies for oncology and transplant indications. The intraday decline tracks the company’s recent earnings announcement timing and cautious market commentary across biotech. Market participants cite slower-than-expected trial updates and negative valuation metrics as triggers. For background see coverage on Investing.com and related sector comparisons on Investing.com competitor pages.

MAAT.PA financials and valuation

MaaT Pharma reports an EPS of -2.15 and a negative PE of -2.84, reflecting ongoing clinical-stage losses. Market cap stands at €92,192,759.00 with 15,113,567 shares outstanding. Price-to-sales is high at 23.51 and price-to-book at 11.11, signalling elevated valuation relative to current revenues and book value. Current ratio is 2.22, and cash per share is €0.99, indicating short-term liquidity but continued cash burn.

Technical outlook, indicators and Meyka grade

Technically, MAAT.PA shows oversold signals: RSI 34.40, CCI -206.82, and Williams %R -90.67, while MACD histogram is negative. Immediate support sits at the intraday low €5.14 and a key longer-term support at the 200-day average €5.12.

Meyka AI rates MAAT.PA with a score of 65.83 out of 100 | Grade: B | Suggestion: HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst sentiment. These grades are not guaranteed and we are not financial advisors.

Risks, catalysts and sector context

Risks include clinical trial timing, cash runway and continued negative EPS; debt-to-equity is 1.74, which raises leverage concerns for a small cap biotech. Catalysts that could reverse momentum: positive trial readouts for MaaT013 or MaaT033, licensing updates, or clearer guidance on cash burn. Healthcare sector averages (Europe) show higher PE and ROE, underlining biotech’s divergence from larger pharma peers.

Trading strategy and price targets for MAAT.PA stock

Short-term traders may watch €5.14 support and the 50-day average €6.76 as resistance. We outline a conservative price target range: a near-term recovery target of €6.50 and a cautious 12-month target of €4.50 if trial delays persist. Use strict risk limits given volatility; set stop-loss orders below €5.00 for short-term positions.

Final Thoughts

MAAT.PA stock posted a steep intraday decline to €5.24 on 31 Mar 2026, driven by weak clinical-readout sentiment and valuation scrutiny. Our technical read shows oversold momentum but limited near-term support below €5.14. Meyka AI’s forecast model projects a monthly figure of €6.94 and a 12-month projection of €3.22, implying a near-term upside of +32.64% to the monthly forecast and a longer-term downside of -38.51% to the yearly projection versus the current price. We present a balanced range: a recovery target near €6.50 and a downside case target of €4.50, reflecting cash-burn and trial risk. Traders should weigh catalysts such as trial updates or financing against high price-to-sales and negative earnings. Meyka AI provides this AI-powered market analysis platform data-driven view as a guide; forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.